Paul Aisen, NIA-appointed Director of the Alzheimer’s Disease Cooperative Study and Professor of Neurosciences at the University of California, San Diego, has been conducting therapeutic research on Alzheimer’s disease for the past two decades. Dr. Aisen’s research focuses on inflammatory mechanisms in the brain and the development of new treatment strategies for Alzheimer’s disease and other neurodegenerative diseases. As Director of the ADCS, he collaborates with pharmaceutical companies on drug development and designing and directing multicenter randomized controlled trials to evaluate the safety and efficacy of new treatments. Therapeutic approaches under investigation include secretase modulators, amyloid-binding compounds, cholinesterase inhibitors, nicotine, antioxidants and anti-inflammatory drugs.